Clene Nanomedicine Inc.

Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function. Its nanotherapeutics target cellular energy impairments common to many diseases, and its nanotherapeutic platform enables the creation of clean-surfaced, catalytically-active nanocrystals for therapeutic use. The company is advancing a pipeline of these nanotherapeutics to address high unmet medical needs, starting with neurodegenerative diseases. Its lead drug candidate, CNM-Au8, is an oral suspension of clean-surfaced, catalytically-active gold nanocrystals that is in development as a disease-modifying treatment for Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease.

Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function. Its nanotherapeutics target cellular energy impairments that are common to many diseases. The company's nanotherapeutic platform enables the creation of clean-surfaced, catalytically-active nanocrystals for therapeutic use, and it is advancing a pipeline of these nanotherapeutics to address high unmet medical needs, starting with neurodegenerative diseases. Its lead drug candidate, CNM-Au8, is an oral suspension of clean-surfaced, catalytically-active gold nanocrystals resulting from patented manufacturing breakthroughs. CNM-Au8 is currently in development as a disease-modifying treatment for Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease, and there have been over 1,000 patient years of CNM-Au8 exposure without identified safety signals.

Clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function.

• CNM-Au8

  Lead drug candidate; an oral suspension of clean-surfaced, catalytically-active gold nanocrystals, in development as a disease-modifying treatment for Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease.

1. 1Clene Inc. – Nanomedicine in Pharmaceutical Researchclene.com
2. 2Our Team – Clene Inc.clene.com
3. 3About CNM-Au8® – Clene Inc.clene.com